These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34409596)

  • 1. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
    Cross NCP; Godfrey AL; Cargo C; Garg M; Mead AJ;
    Br J Haematol; 2021 Nov; 195(3):338-351. PubMed ID: 34409596
    [No Abstract]   [Full Text] [Related]  

  • 2. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
    Tefferi A
    J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic/myeloproliferative disorders.
    Malcovati L; Cazzola M
    Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic mechanisms in myeloproliferative disorders.
    Delhommeau F; Pisani DF; James C; Casadevall N; Constantinescu S; Vainchenker W
    Cell Mol Life Sci; 2006 Dec; 63(24):2939-53. PubMed ID: 17131059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity?
    Rudzki Z; Giles L; Cross NC; Lumley M
    Br J Haematol; 2012 Mar; 156(5):558. PubMed ID: 22224867
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
    Helbig G; Kyrcz-Krzemien S
    Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
    [No Abstract]   [Full Text] [Related]  

  • 9. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.
    Xia D; Hasserjian RP
    Am J Hematol; 2016 Dec; 91(12):1277-1280. PubMed ID: 27727468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
    Dong L; Shen XL; Wei W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
    Tefferi A; Skoda R; Vardiman JW
    Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
    Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
    Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
    Cazzola M; Kralovics R
    Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
    von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
    Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
    [No Abstract]   [Full Text] [Related]  

  • 19. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
    Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
    Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
    Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.